Gilead Sciences, Inc. (NASDAQ:GILD) Annual Evercore ISI HealthCONx Healthcare Conference December 4, 2024 11:40 AM ET Company Participants Andrew Dickinson - Chief Financial Officer Conference Call Participants Umer Raffat - Evercore Umer Raffat Excellent. Well, thank you guys for joining us. Really excited to have Gilead management again in Miami. I think the conference is not complete without you being here, Andy. So, thank you for being here. Andrew Dickinson I'm thrilled to be here again. Thank you. Ume ...

Gilead Sciences, Inc. (NASDAQ:GILD) Piper Sandler 36th Annual Healthcare Conference December 3, 2024 11:00 AM ET Company Participants Andy Dickinson - Chief Financial Officer Conference Call Participants Joe Catanzaro - Piper Sandler Joe Catanzaro Great. So thanks everybody for joining us here day one Annual Piper Sandler Healthcare Conference. I'm Joe Catanzaro, one of the biotech analysts here at Piper. It's my pleasure to welcome Gilead and their CFO, Andy Dickinson. Andy, thanks so much for joining us. ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Gilead Sciences (GILD) .Gilead currently has an average brokerage recommen ...

Biotech giant Gilead Sciences, Inc.’s (GILD) shares have risen 44.2% in the past six months compared with the industry’s growth of 1.1%. The stock has also outperformed the sector and the S&P 500. It has grown steadily in the past six months.Earlier this month, Gilead reported better-than-expected third-quarter results and raised its annual earnings guidance yet again. Revenues increased 7% from the year-ago quarter’s level due to high HIV and Veklury sales.Approval of new drugs and encouraging pipeline pro ...

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our St ...

Summary of Gilead Sciences, Inc. Conference Call Company Overview - **Company**: Gilead Sciences, Inc. (NASDAQ:GILD) - **Event**: 2024 Jefferies London Healthcare Conference - **Date**: November 20, 2024 - **Participants**: Dan O'Day (Chairman and CEO), Andy Dickinson (CFO) Key Points Industry and Market Position - Gilead is in a strong position within the biotechnology industry, particularly in the HIV market, with a robust and growing franchise [6][8] - The company has minimal patent expiries until 2033, providing a stable revenue outlook [6] - Gilead is diversifying into oncology and liver diseases, with oncology representing approximately 11% of its business, equating to around $3 billion in annual turnover [7] Financial Performance and Growth Outlook - Gilead reported a 7% growth year-to-date through Q3, excluding Veklury, and expects a 5% to 6% growth in its base business for the year [8][10] - The company anticipates a one-time impact from the IRA Part D reform on its HIV business in 2025, but expects overall business growth to continue [9][13] - Gilead's operating margin was reported at 43% in Q3, with potential for higher margins when excluding one-time costs [16] HIV Market Developments - Gilead is preparing to launch lenacapavir, a new PrEP drug, which has shown high efficacy in trials and is expected to redefine the PrEP market [23][24] - The current PrEP market is underpenetrated, with only about 400,000 out of 1.2 million at-risk individuals in the U.S. currently using PrEP [24][49] - The company expects lenacapavir to significantly increase adherence rates compared to daily oral medications, potentially improving compliance from 50-60% to 80-90% [27][28] Long-Acting Treatments and Future Pipeline - Gilead is committed to developing long-acting treatments for HIV, with plans to launch multiple new long-acting therapies before 2033 [56][59] - The company is also focusing on expanding its treatment options to address the 25-30% of patients who are not currently virologically suppressed [58][60] Oncology and Liver Disease Opportunities - Gilead is excited about its CAR-T program for multiple myeloma, which is expected to be competitive in the market [66][70] - The recently launched drug Livdelzi for primary biliary cholangitis (PBC) is anticipated to be a significant opportunity, with strong efficacy data and a focus on reducing patient itch [72][75] - Gilead is exploring opportunities in NASH/MASH and obesity, with ongoing studies and potential new drug developments [78][80] Conclusion - Gilead Sciences is positioned for continued growth with a strong focus on HIV, oncology, and liver diseases, backed by a solid financial performance and a promising pipeline of new therapies [5][10][14]

Core Insights - Gilead Sciences, Inc. announced positive interim results from the Phase 3 ASSURE study for Livdelzi, showing 81% of participants with primary biliary cholangitis (PBC) achieved a composite biochemical response [1] - The FDA granted accelerated approval for Livdelzi in August for PBC treatment, indicating its potential in the market [3] Efficacy and Safety Data - In the ASSURE study, 41% of participants achieved normalization of alkaline phosphatase (ALP) levels, a key liver function biomarker [2] - Livdelzi demonstrated a significant reduction in ALP levels compared to placebo, with a decrease of approximately 35% in participants with cirrhosis and 43.5% in those without cirrhosis [3] - The treatment was generally well tolerated, with no new safety signals reported over three years of exposure [2] Additional Findings - Secondary analysis from the RESPONSE trial indicated that Livdelzi led to near resolution of pruritus in 26.5% of participants with a baseline NRS of ≥4 and 18.8% with NRS ≥7, compared to 0% in the placebo group [3] Market Reaction - Following the announcement, Gilead's stock price decreased by 3.48%, closing at $88.90 [4]

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?Let's take a look at what these Wall Street heavyweights have to say about Gilead Sciences (GILD) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Gilead currently has an average brokerage recommendation ...

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Gilead Sciences (GILD) or Vertex Pharmaceuticals (VRTX) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank is a proven stra ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value, $0.001 per share GILD The Nasdaq Global Select Market FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ ...